-
14:40
-14:50
Founding history of EAGOT
-
14:50
-15:00
JGOG 3025 study
-
15:00
-15:10
Non BRCA HRR gene mutation landscape and treatment outcomes with PARP inhibitors
-
15:10
-15:20
When and how to undertake lymphadenectomy in immunoncology era
-
15:20
-15:30
PI3Kα inhibitor monotherapy for OCCC with concurrent PIK3CA and ARID1A mutations
-
15:30
-15:40
Q&A

